Autologous stem cell transplantation for mantle cell lymphoma - single centre experience

• Published in: Contemporary oncology (Poznan, Poland) Vol. 17; no. 5; pp. 456 - 459
• Main Authors: Szcześniak, Magdalena, Armatys, Anna, Kurzawa, Rafał, Kandzia, Tomasz, Kozioł, Dominika, Frankiewicz, Andrzej, Kopińska, Anna, Krawczyk-Kuliś, Małgorzata, Kyrcz-Krzemień, Sławomira, Helbig, Grzegorz
• Format: Journal Article
• Language: English
• Published: Poland Termedia Publishing House 2013
• Subjects: Original Paper; mantle cell lymphoma; results; autologous stem cell transplantation
• DOI: 10.5114/wo.2013.37223
• EISSN: 1897-4309
• ISSN: 1428-2526

Mantle cell lymphoma (MCL) is a B-cell neoplasm showing resistance to conventional chemotherapy. High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) may result in higher progression-free (PFS) and overall survival (OS) when used as a consolidation for younger and fit patients.
We retrospectively evaluated the results of ASCT for MCL. Patients were transplanted after achieving first or subsequent complete or partial response after conventional chemotherapy.
Twenty patients (7 male and 13 female) at median age of 59 years (range 41-68) were included. 90% of transplanted patients had stage III/IV disease at diagnosis and low, intermediate and high MIPI scores occurred in 5, 9 and 6 patients respectively. Induction chemotherapy consisted of the R-CHOP regimen in all patients except one who received R-CVAD. The disease status at transplant was as follows: first complete response (n = 13); second complete response (n = 4) and partial response (n = 3). The conditioning regimen prior to ASCT consisted of CBV and BEAM for 18 and 2 patients, respectively. The transplant-related mortality was 0% at day 100. Median OS and PFS were 48 and 29.8 months, respectively. The estimated 5-year OS and PFS were found to be 52% and 35%, respectively. After median follow-up after ASCT of 36 months (range 11-73), 10 patients were alive with 8 remaining in complete remission (CR) whereas 2 relapsed and received salvage chemotherapy. Ten patients died from disease recurrence and subsequent chemoresistance.
ASCT as a consolidation for MCL patients is found to be an effective and safe procedure.